**Detailed Summary of the Prescribed Products Regulations**

---

**Regulatory Authority and Legal Basis:**

The *Prescribed Products Regulations* were issued by **His Excellency the Governor General in Council**, acting on the **recommendation of the Minister of Finance**. This action is authorized under three key federal statutes:

1. **Section 978a of the Bank Act** – Provides the legal foundation for regulating certain financial products, particularly those involving deposit-taking institutions and related financial instruments.
2. **Section 463c of the Cooperative Credit Associations Act** – Applies to cooperative credit associations (e.g., credit unions), enabling the regulation of specific financial products offered by such institutions.
3. **Section 531e of the Trust and Loan Companies Act** – Governs trust and loan companies, allowing for the designation of certain products as "prescribed" for regulatory oversight.

These statutory provisions empower the government to identify and define financial products that are subject to specific regulatory scrutiny, particularly in relation to consumer protection, risk management, and transparency.

---

**Purpose of the Regulations:**

The primary objective of the *Prescribed Products Regulations* is to **identify and classify specific financial products** that are subject to heightened regulatory oversight under the *Cooperative Credit Associations Act* and the *Trust and Loan Companies Act*. These products are considered high-risk or complex due to their structure, potential for misrepresentation, or the exposure they create for investors.

By formally prescribing these products, the regulations ensure that financial institutions offering them—such as credit unions and trust and loan companies—must comply with enhanced disclosure, risk management, and consumer protection requirements.

---

**Prescribed Products Defined:**

The Regulations prescribe two types of financial products:

1. **Deposit Type Instruments (DTIs)**  
   - As defined in the *Deposit Type Instruments Regulations*, these are financial products that mimic the characteristics of deposits (e.g., guaranteed returns, principal protection) but may carry different risk profiles or structures.  
   - Examples include structured deposits, certain types of investment certificates, or instruments that offer fixed returns with limited risk exposure.  
   - These instruments are considered to be functionally similar to deposits but may involve investment components or derivatives.  
   - Their classification as "prescribed" means they are subject to specific rules regarding marketing, disclosure, and risk communication.

2. **Principal Protected Notes (PPNs)**  
   - As defined in the *Principal Protected Notes Regulations*, these are investment products that guarantee the return of the principal amount to investors, regardless of market performance.  
   - In return, investors typically receive a fixed or variable return (often tied to market indices or interest rates), but the return is capped or structured to ensure principal safety.  
   - PPNs are considered high-risk due to their complex structure, potential for misleading marketing, and the possibility of significant returns or losses beyond the principal.  
   - The regulation ensures that these products are clearly disclosed and that investors are fully informed of the risks involved.

---

**Applicable Legal Provisions:**

The prescribed products are subject to specific regulatory requirements under the following sections of the relevant Acts:

- **Section 385.131 and 385.241 of the Cooperative Credit Associations Act** – These provisions require cooperative credit associations to adhere to strict rules when offering prescribed products, including mandatory disclosures, suitability assessments, and risk disclosures to members.
- **Section 434.1 and 442.1 of the Trust and Loan Companies Act** – These sections impose similar obligations on trust and loan companies, ensuring that products offered to clients are transparent, properly disclosed, and aligned with the risk tolerance of the investor.

These sections reinforce the requirement that institutions must:
- Clearly disclose the risks, fees, and potential returns,
- Ensure that the product is suitable for the investor’s financial situation,
- Maintain accurate records, and
- Comply with consumer protection standards.

---

**Effective Date:**

The *Prescribed Products Regulations* came into force on **November 1, 2011**. This date marks the point at which financial institutions began to be subject to the enhanced regulatory requirements for the prescribed products listed in the Regulations.

---

**Key Implications:**

- **Enhanced Consumer Protection**: By clearly defining and regulating products such as PPNs and DTIs, the Regulations aim to protect consumers from misleading or overly complex financial products.
- **Transparency and Disclosure**: Institutions must provide clear, accessible, and comprehensive information to clients about the risks and benefits of prescribed products.
- **Risk Management Oversight**: Financial institutions are required to assess and manage the risks associated with these products, particularly in cases where returns are guaranteed or tied to volatile markets.
- **Regulatory Consistency**: The Regulations ensure a consistent application of rules across different types of financial institutions (credit unions, trust and loan companies) when offering similar products.

---

**Conclusion:**

The *Prescribed Products Regulations* serve as a critical tool in the Canadian financial regulatory framework, ensuring that certain high-risk or complex financial instruments—particularly those involving principal protection or deposit-like features—are properly governed. By designating deposit type instruments and principal protected notes as "prescribed," the Regulations establish a clear legal basis for enhanced disclosure, suitability, and consumer protection requirements, ultimately promoting financial stability and investor confidence.

These regulations reflect a broader regulatory trend in Canada to increase transparency and accountability in financial products, especially those that may obscure risk through marketing or structure.